openPR Logo
Press release

Investigation announced for Investors in Ocugen, Inc. (NASDAQ: OCGN) over possible Violations of Securities Laws

06-18-2021 01:35 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation for investors in Ocugen, Inc. (NASDAQ: OCGN) shares over potential securities laws violations by Ocugen, Inc.

An investigation for investors in Ocugen, Inc. (NASDAQ: OCGN) shares over potential securities laws violations by Ocugen, Inc.

Ocugen, Inc is under investigation over potential securities laws violations in connection with certain financial statements.

Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Ocugen, Inc. (NASDAQ: OCGN) concerning whether a series of statements by Ocugen, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Malvern, PA based Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.
On May 26, 2021, Ocugen, Inc. announced its plan to submit an Emergency Use Authorization (EUA) application for COVAXIN, a COVID-19 vaccine, to the U.S. Food & Drug Administration (FDA) in June 2021.
Then on June 10, 2021, Ocugen, Inc. said it would no longer pursue a EUA for Covaxin and would instead aim to file for a full U.S. approval of the shot.

Shares of Ocugen, Inc. (NASDAQ: OCGN) declined from $11.01 per share on June 8, 2021 to $5.96 per share on June 14, 2021.

Those who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in Ocugen, Inc. (NASDAQ: OCGN) over possible Violations of Securities Laws here

News-ID: 2308142 • Views: 727

More Releases from Shareholders Foundation

Deadline on Nov. 12th coming up in Lawsuit for Investors in Longeveron Inc. (NAS …
A deadline is coming up on November 12, 2021 in the lawsuit filed for certain investors of Longeveron Inc. (NASDAQ: LGVN) over alleged securities laws violations by Longeveron Inc. Investors who purchased shares of Longeveron Inc. (NASDAQ: LGVN) have certain options and there are strict and short deadlines running. Deadline: November 12, 2021. NASDAQ: LGVN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to the
Investigation announced for Long-Term Investors in shares of Ardelyx, Inc. (NASD …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Ardelyx, Inc. Investors who are current long term investors in Ardelyx, Inc. (NASDAQ: ARDX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: ARDX stocks follows a lawsuit filed against Ardelyx, Inc. over alleged
Investigation announced for Investors in shares of Organogenesis Holdings Inc. ( …
An investigation was announced concerning potential securities laws violations by Organogenesis Holdings Inc. in connection with certain financial statements. Investors who purchased shares of Organogenesis Holdings Inc. (NASDAQ: ORGO), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Organogenesis Holdings Inc. (NASDAQ: ORGO) concerning whether a
Investigation announced for Long-Term Investors in shares of AdaptHealth Corp. ( …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of AdaptHealth Corp. Investors who are current long term investors in AdaptHealth Corp. (NASDAQ: AHCO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: AHCO stocks follows a lawsuit filed against AdaptHealth Corp. over alleged

All 5 Releases


More Releases for Ocugen

COVID-19 Impact on Retinitis Pigmentosa Treatment & Management Market Overview a …
Retinitis Pigmentosa Treatment & Management Market is expected to grow significantly over next few years and generate considerable market for Retinitis Pigmentosa Treatment & Management. Market Report Expert has recently published a research report titled, “Retinitis Pigmentosa Treatment & Management Market Outlook and Statistics, 2020-2026". The report has been prepared by experienced and knowledgeable market analysts, researchers, market experts, and key option leaders within Retinitis Pigmentosa Treatment & Management market. It
Retinitis Pigmentosa (RP) Market 2025 : Ocugen, Inc., ReGenX Biosciences, LLC, S …
Global Retinitis Pigmentosa (RP) Market: Snapshot Retinitis pigmentosa, is a condition where patients typically loses ability to see at night in young years, side vision in middle age, and focal vision in later in his/her life due to relentless loss of cone photoreceptor cells. Proportions of retinal capacity, for example, the electroretinogram, demonstrate that photoreceptor capacity is decreased normally quite before symptomic night visual impairment, visual-field scotomas, or diminished visual sharpness
Retinitis Pigmentosa (RP) Market | Amarantus BioScience Holdings, Inc., Ocugen, …
Global Retinitis Pigmentosa (RP) Market: Snapshot Retinitis pigmentosa, in which patients usually lose night vision in teenage years, side vision in middle age, and central vision in later life because of steady loss of cone photoreceptor cells and rod. Measures of retinal function, such as the electroretinogram, indicate that photoreceptor function is reduced usually several years before visual-field scotomas, symptomic night blindness, or reduced visual acuity arise. Get Sample Copy of
Retinitis Pigmentosa (RP) Market | Amarantus BioScience Holdings, Inc., Ocugen, …
Global Retinitis Pigmentosa (RP) Market: Snapshot Retinitis pigmentosa, in which patients usually lose night vision in teenage years, side vision in middle age, and central vision in later life because of steady loss of cone photoreceptor cells and rod. Measures of retinal function, such as the electroretinogram, indicate that photoreceptor function is reduced usually several years before visual-field scotomas, symptomic night blindness, or reduced visual acuity arise. Get Brochure of the
Choroidal Neovascularization Therapeutics Pipeline Analysis 2018 | Graybug Visio …
Choroidal neovascularization is a type of medical condition in which new blood vessels are formed from choroid and extend into the subretinal space, or subretinal pigment epithelium, or a combination of both. Download the sample report @ https://www.pharmaproff.com/request-sample/1122 The disease can be symptomatized by a painless loss of vision, paracentral or central scotoma, and metamorphopsia. Choroidal neovascularization can be diagnosed by indocyanine green angiography, spectral domain optical coherence tomography, and fluorescein angiography.
Retinitis Pigmentosa (RP) Market Estimated to Flourish at by 2025 | Amarantus Bi …
Global Retinitis Pigmentosa (RP) Market: Snapshot Retinitis pigmentosa, in which patients usually lose night vision in teenage years, side vision in middle age, and central vision in later life because of steady loss of cone photoreceptor cells and rod. Measures of retinal function, such as the electroretinogram, indicate that photoreceptor function is reduced usually several years before visual-field scotomas, symptomic night blindness, or reduced visual acuity arise. Get Brochure of the